Eagle Pharmaceuticals Risks Nasdaq Delisting Over Filing Delays

Eagle Pharmaceuticals Inc (EGRX) has issued an announcement.

Eagle Pharmaceuticals, Inc. is currently facing non-compliance issues with Nasdaq’s listing requirements due to delays in filing its annual and quarterly financial reports. The company has received a notice regarding its failure to file the necessary reports and is at risk of being delisted if it cannot regain compliance. Although Eagle Pharmaceuticals has been granted an extension until May 13, 2024, to address these issues, it has indicated doubt in meeting this deadline and may face delisting proceedings, which could lead to a hearing to maintain its Nasdaq listing.

For detailed information about EGRX stock, go to TipRanks’ Stock Analysis page.